Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 3/20 | 0.48 |
| ▸ | SYK | P43405 | 7/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | KLK3 | P07288 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048001 | 0.86 | ZAP70 (0.62) | ZAP70SYKPDE5APIK3CBPIK3CA | |
| SCHEMBL1043289 | 0.82 | ZAP70 (0.54) | ZAP70SYKGRM2 | |
| SCHEMBL27806186 | 0.79 | GSK3B (0.42) | ZAP70SYKMAP4K1 | |
| SCHEMBL27806165 | 0.79 | ZAP70 (0.42) | ZAP70SYKGRM2PIK3CBKLK3 | |
| SCHEMBL1058951 | 0.78 | SYK (0.63) | SYK | |
| SCHEMBL27806125 | 0.73 | TLR7 (0.42) | ZAP70SYK | |
| SCHEMBL1049131 | 0.73 | ZAP70 (0.71) | ZAP70SYK | |
| SCHEMBL1050184 | 0.72 | ZAP70 (0.51) | ZAP70AURKATTKAURKBINCENP | |
| SCHEMBL27826750 | 0.72 | ZAP70 (0.58) | ZAP70SYKPIK3CBPIK3CA | |
| SCHEMBL1159116 | 0.70 | ZAP70 (0.46) | ZAP70SYKGRM2PDE5APIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | claimed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| EP-2238137-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009097287-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | ZAP70 4/4885SYK 2/4885GRM2 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.